%20(1).webp)
Retatrutide Not Working? 4 Reasons Weight Loss Can Stall and What to Target
Updated: Sep 7
Retatrutide can produce substantial reductions in body weight, but response is not identical in everyone. In the Phase 2 obesity trial, the highest-dose group reached an average weight reduction of 24.2% at 48 weeks. Metabolic health, insulin sensitivity, diet, activity and individual biology can still influence how strongly someone responds. Read the Phase 2 trial on PubMed.
When progress slows, the most useful question is not simply, “Should the amount be increased?” It is: what may be limiting the body’s response?
Quick answer: A retatrutide weight-loss plateau can be influenced by insulin resistance, normal metabolic adaptation, thyroid-related changes, liver dysfunction, systemic inflammation, shifts in food intake or activity, and ordinary measurement noise. Confirm that the stall is real, review the fundamentals, and use objective markers to identify the most relevant target. |
Why Retatrutide Weight Loss Can Plateau
Retatrutide activates GLP-1, GIP and glucagon receptors. Together, these pathways can influence appetite, glucose control and energy use. That does not make weight loss perfectly linear.
Scale weight can remain flat for several weeks because of water retention, bowel contents, sodium intake, menstrual-cycle changes, reduced movement or a smaller calorie gap after weight has already fallen. A true plateau is a sustained trend across several weeks—not one unchanged weigh-in.
Before looking for a deeper cause, compare weekly average weight, waist measurement, food intake, activity, sleep and adherence. If the plateau persists, the four-target framework below helps organize the next questions.
1. High Insulin and Insulin Resistance
What to look at
Fasting insulin
Fasting glucose
HOMA-IR
HbA1c
Triglycerides and waist trend
Insulin resistance means muscle, liver and fat cells do not respond to insulin as efficiently. The body may compensate by producing more insulin. This metabolic pattern often travels with central fat gain, fatty liver, higher triglycerides and low-grade inflammation.
The point is not that insulin “blocks” all fat loss. It is that poor insulin sensitivity can reveal a broader metabolic environment that deserves attention when retatrutide progress has stalled.
What to target
The insulin-resistance pathway focuses on metabolic flexibility, mitochondrial signalling, food quality and movement. Research components discussed in this framework include MOTS-C, BPC-157, Thymosin Alpha-1, alpha-lipoic acid, chromium picolinate and zinc picolinate, alongside reduced refined-carbohydrate exposure and time-restricted eating when appropriate.
MOTS-C is especially relevant to the pathway discussion. Laboratory research found that it activates AMPK and influences glucose use, fatty-acid metabolism and insulin sensitivity. View the MOTS-C study on PubMed. Human supplementation studies of chromium have also reported changes in fasting glucose, insulin and HOMA-IR, although results vary across populations. View the meta-analysis on PubMed.
The practical focus remains simple: improve the metabolic environment rather than treating every plateau as an appetite problem.
2. Low Free T3 and High Reverse T3
What to look at
TSH
Free T4
Free T3
Reverse T3 as supporting context
Ferritin, symptoms and overall energy availability
Weight loss changes metabolism. As body weight falls and energy intake stays lower, the body can conserve energy by reducing total expenditure. This is commonly called adaptive thermogenesis. Research has shown that this adaptation can meaningfully affect how easily some people continue losing weight. View the adaptive-thermogenesis study on PubMed.
Thyroid markers must be interpreted together. A single reverse-T3 result cannot explain a plateau by itself, and low energy availability, illness, iron status, sleep and stress can change the wider picture.
What to target
This pathway focuses on thyroid conversion, micronutrient sufficiency, liver function, antioxidant capacity and the stress created by prolonged dieting. Components retained from the earlier framework include NAC, milk thistle, selenium, zinc picolinate, BPC-157 and Thymosin Alpha-1.
The distinction matters: a thyroid-pattern plateau and an insulin-resistance plateau may look similar on the scale, but they point toward different biology.
3. Elevated or Unstable Liver Enzymes
What to look at
ALT
AST
GGT
Alkaline phosphatase and bilirubin when relevant
Alcohol, medication, supplement and recent-training context
The liver is a central metabolic organ. It helps regulate glucose, process fats and amino acids, store glycogen, transport lipids and metabolize hormones. Liver dysfunction and insulin resistance are therefore closely connected.
Retatrutide itself has shown a strong effect on liver fat. In a randomized Phase 2a substudy, every tested retatrutide dose reduced liver fat more than placebo at 24 weeks, with the largest groups averaging reductions above 80%. View the liver-fat trial on PubMed.
Persistently abnormal ALT, AST or GGT still provides useful information. AST can also rise after hard training or muscle injury, so the pattern and context matter more than one isolated number.
What to target
The liver pathway centres on NAC, milk thistle, BPC-157 and 5-Amino-1MQ. NAC and milk thistle represent the antioxidant and liver-support side of the framework. BPC-157 is discussed around tissue-repair pathways. Earlier liver-injury models reported effects of BPC-157 on liver pathology and enzyme changes. View the BPC-157 liver study on PubMed.
5-Amino-1MQ targets nicotinamide N-methyltransferase, or NNMT, a metabolic enzyme connected with NAD-related biology. A 2024 study reported improvements in body composition, insulin sensitivity and liver findings in diet-induced obesity models. View the 5-Amino-1MQ study on PubMed.
The key idea is simple: if liver markers are abnormal, investigate the liver and metabolic pattern instead of treating the situation like ordinary appetite resistance.
4. High CRP and Systemic Inflammation
What to look at
CRP or hs-CRP trend
Recent illness, injury or hard training
Waist trend and other metabolic markers
CRP, or C-reactive protein, is a general marker of inflammation. It does not identify the source by itself, but a persistent elevation can help show that the metabolic environment is not quiet.
Obesity, central fat accumulation, inflammation and insulin resistance frequently overlap. Reviews describe links among adipose-tissue cytokines, CRP and disrupted insulin signalling. View the inflammation and insulin-resistance review on PubMed.
What to target
The inflammation pathway centres on Thymosin Alpha-1, BPC-157 and KPV.
KPV is the three-amino-acid fragment Lys-Pro-Val. Cell and animal research found that it reduced NF-κB and MAP-kinase inflammatory signalling and lowered pro-inflammatory cytokine output. View the KPV study on PubMed. Thymosin Alpha-1 is studied as an immune-regulating peptide rather than as a direct appetite compound. View the Thymosin Alpha-1 review on PubMed.
This creates a different strategy from the high-insulin pathway: the target is inflammatory and immune signalling, not simply stronger appetite suppression.
What Labs Can Help Identify the Problem?
Target | Useful markers and context | Research components retained |
|---|---|---|
High insulin / high HOMA-IR | Fasting insulin, fasting glucose, HOMA-IR, HbA1c, triglycerides, waist trend | MOTS-C, BPC-157, Thymosin Alpha-1, alpha-lipoic acid, chromium, zinc, dietary changes and time-restricted eating |
Low free T3 / high reverse T3 | TSH, free T4, free T3, reverse T3 as context, ferritin, symptoms and energy availability | NAC, milk thistle, selenium, zinc, BPC-157 and Thymosin Alpha-1 |
Abnormal liver enzymes | ALT, AST, GGT, alkaline phosphatase and bilirubin; review alcohol, medications, supplements and muscle injury | NAC, milk thistle, BPC-157 and 5-Amino-1MQ |
High CRP | CRP or hs-CRP trend; rule out acute illness, injury and other inflammatory causes | Thymosin Alpha-1, BPC-157 and KPV |
How to Use the Four-Target Framework
Confirm the plateau. Use weekly averages and waist measurements rather than reacting to a few days of scale noise.
Check the basics. Review intake, protein, sleep, movement, resistance training and consistency.
Look for a pattern. Use symptoms and repeatable lab trends to decide whether insulin resistance, thyroid adaptation, liver stress or inflammation deserves closer attention.
Match the target. Choose research questions and supportive strategies that fit the identified pathway rather than combining everything automatically.
Reassess. Track the same measurements over time so decisions are based on trends.
Frequently Asked Questions
Why am I not losing weight on retatrutide?
A short stall may be water or measurement noise. A longer plateau can reflect a smaller calorie gap, lower activity, metabolic adaptation, insulin resistance, thyroid-related changes, liver dysfunction or inflammation.
Can you plateau on retatrutide?
Yes. Weight loss is rarely linear. As body mass falls, the body usually requires less energy, and hunger, movement and water balance can change.
Does insulin resistance affect retatrutide weight loss?
Insulin resistance does not make fat loss impossible, but it can signal a wider metabolic pattern involving higher insulin, fatty liver, inflammation and impaired glucose handling.
Can thyroid function affect a weight-loss plateau?
Thyroid hormones help regulate energy expenditure. Low energy availability and prolonged weight loss can also alter thyroid-related markers, so the full pattern matters.
What blood tests can help investigate a plateau?
Common starting points include fasting glucose, fasting insulin, HbA1c, a lipid panel, TSH, free T4, free T3, ferritin, CRP or hs-CRP, ALT, AST and GGT. Selection and interpretation depend on the individual context.
Can inflammation affect metabolic weight loss?
Persistent inflammation often overlaps with obesity and insulin resistance. CRP can help identify that pattern, but it does not show the cause by itself.
The Bigger Picture
When retatrutide appears to stop working, the answer is not always more of the same approach. First confirm that the plateau is real. Then separate ordinary adaptation from a clearer insulin, thyroid, liver or inflammatory pattern.
The strongest plan is the one built around the actual limiting factor. That is the purpose of the four-target framework: turn a vague plateau into a set of specific, measurable questions.
Explore Kelden Peptides Canada research products, review the Peptide Research Hub, or read what peptide purity, sterility and endotoxin tests actually mean.
Related Peptide Research Articles
References
Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine. 2023. View on PubMed
Sanyal AJ, Kaplan LM, Frías JP, et al. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nature Medicine. 2024. View on PubMed
Tremblay A, Royer MM, Chaput JP, Doucet E. “Adaptive thermogenesis can make a difference in the ability of obese individuals to lose body weight.” International Journal of Obesity. 2013. View on PubMed
Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015. View on PubMed
Asbaghi O, et al. “Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis.” Pharmacological Research. 2020. View on PubMed
Sikiric P, et al. “Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by restraint stress, vascular ligation or CCl4 administration.” Life Sciences. 1993. View on PubMed
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. “Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.” Diabetes, Obesity and Metabolism. 2024. View on PubMed
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008. View on PubMed
Greenfield JR, Campbell LV. “Relationship between inflammation, insulin resistance and type 2 diabetes: cause or effect?” Current Diabetes Reviews. 2006. View on PubMed
Mao L, et al. “Thymosin alpha 1—Reimagine its broader applications in the current era.” International Immunopharmacology. 2023. View on PubMed
